Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

Autor:	Turner MA; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; VA San Diego Healthcare System, San Diego, CA, U.S.A., Hollandsworth HM; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; VA San Diego Healthcare System, San Diego, CA, U.S.A., Nishino H; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; VA San Diego Healthcare System, San Diego, CA, U.S.A., Amirfakhri S; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; VA San Diego Healthcare System, San Diego, CA, U.S.A., Lwin TM; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A., Lowy AM; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A., Kaur S; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A., Natarajan G; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A., Mallya K; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A., Hoffman RM; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; VA San Diego Healthcare System, San Diego, CA, U.S.A.; AntiCancer, Inc., San Diego, CA, U.S.A., Batra SK; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A., Bouvet M; Department of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; mbouvet@ucsd.edu.; VA San Diego Healthcare System, San Diego, CA, U.S.A.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2022 Jan-Feb; Vol. 36 (1), pp. 57-62.
DOI:	10.21873/invivo.12676
Abstrakt:	Background: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. Results: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). Conclusion: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance. (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu